Janardhan Sridhara, Ph.D
Director- AI & Cheminformatics at PharmCADD- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
English, Hindi and Telugu Professional working proficiency
Topline Score
Bio
Credentials
-
Splunk 7.x Fundamentals Part 1 (IOD)
Splunk - NYCAug, 2020- Nov, 2024 -
Splunk 7.x Fundamentals Part 2 (IOD)
Splunk - NYCAug, 2020- Nov, 2024 -
Deep Learning Fundamentals
Cognitive ClassMar, 2020- Nov, 2024 -
Machine Learning with Python
Cognitive ClassJan, 2020- Nov, 2024 -
SCALED AZILE FRAMEWORK
SCALED AZILEDec, 2019- Nov, 2024
Experience
-
PharmCADD
-
South Korea
-
Biotechnology Research
-
1 - 100 Employee
-
Director- AI & Cheminformatics
-
Jan 2022 - Present
Involved in strategic AI-enabled platform development and managing inhouse R&D projects. Also involved in identification of novel lead molecules using computational and AIML techniques for oncology & immuno-oncology. Involved in strategic AI-enabled platform development and managing inhouse R&D projects. Also involved in identification of novel lead molecules using computational and AIML techniques for oncology & immuno-oncology.
-
-
-
Cognizant
-
United States
-
IT Services and IT Consulting
-
700 & Above Employee
-
Lead Product Consultant
-
Jul 2021 - Dec 2021
As a SME, involved in development of AI-enabled Drug Discovery (AIDD) Software product for "Merck", to support structure-based & ligand based drug-design core functionalities integrated with advanced machine learning & deep learning workflow systems along with performance metrics & visualization tools. As a SME, involved in development of AI-enabled Drug Discovery (AIDD) Software product for "Merck", to support structure-based & ligand based drug-design core functionalities integrated with advanced machine learning & deep learning workflow systems along with performance metrics & visualization tools.
-
-
-
AstraZeneca
-
United Kingdom
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Lead Data Scientist
-
Feb 2018 - Jul 2021
Provided support and development of (Augmented Drug Design Platform) tailored cheminformatics analyses, tools and scripts to streamline discovery efforts, data analytics, data visualization, predictive modeling and pipelining. Development of new Structure Business Rules for chemistry validation and compound registration of small & large molecules including metallo organic compounds using Pipeline Pilot scripting for future AI research. Provided support and development of (Augmented Drug Design Platform) tailored cheminformatics analyses, tools and scripts to streamline discovery efforts, data analytics, data visualization, predictive modeling and pipelining. Development of new Structure Business Rules for chemistry validation and compound registration of small & large molecules including metallo organic compounds using Pipeline Pilot scripting for future AI research.
-
-
-
Hetero Drugs Ltd
-
India
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Senior Consultant@Discovery R&D
-
Jul 2016 - Jan 2018
Involved in design and development of potent, selective molecules for potential targets involved in inflammatory disorders, oncology, immune-oncology, and infectious diseases by applying informatics and modeling techniques. Developed several predictive statistical models for prediction and prioritization of compounds based optimized drug-likness ADMET properties. Involved in design and development of potent, selective molecules for potential targets involved in inflammatory disorders, oncology, immune-oncology, and infectious diseases by applying informatics and modeling techniques. Developed several predictive statistical models for prediction and prioritization of compounds based optimized drug-likness ADMET properties.
-
-
-
CSIR-INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY
-
Research Services
-
200 - 300 Employee
-
TATA CSIR-OSDD Fellowships Program Manager and Co-convener
-
May 2015 - Jun 2016
As a TATA-CSIR OSDD Fellowships (TCOF) Program Manager and Co-convener, involved in coordination of several Principal Investigators/Scientists and Researcher Scholars across the research organizations working for TB, Malaria in India under Open Source Drug Discovery (OSDD: http://www.osdd.net/) Program lead by CSIR, Government of India by facilitating innovations for encouraging drug discovery in neglected diseases.
-
-
Postdoctoral Research Associate
-
May 2013 - May 2015
As a core investigator, involved in development of Molecular Property Diagnostic Suite (MPDSTB), http://mpds.neist.res.in/ based on the galaxy platform (S. Janardhan, J. Chem. Sci. 2017, 129, 515-531). Design of potential leads and its validation using advanced polypharmacological approaches against drug resistant TB (SAR and QSAR in Envir. Res., 2017, 28, 815-832). The QSAR models were developed using Predictive modeling for the estimation of drug resistant Mtb cell permeability and these models were implemented (code written in Python/Shell script) in MPDS web portal (Mol. BioSyst., 2016, 12, 3377-3384).
-
-
-
Royal Society of Chemistry
-
United Kingdom
-
Non-profit Organizations
-
700 & Above Employee
-
Royal Society of Chemisty (RSC)-Open Source Drug Discovery (OSDD) Ambassador
-
Feb 2014 - Apr 2015
Promoted RSC products (ChemSpider and ChemSpider Synthetic Pages) and OSDD products (Sysborg2 + OSDDChem + OSDDChemDesign) to the scientists and researchers in various national academic institutions and industries by providing an awareness of the importance of Cheminformatics to accelerate the discovery of novel therapies for neglected diseases like TB and Malaria. Promoted RSC products (ChemSpider and ChemSpider Synthetic Pages) and OSDD products (Sysborg2 + OSDDChem + OSDDChemDesign) to the scientists and researchers in various national academic institutions and industries by providing an awareness of the importance of Cheminformatics to accelerate the discovery of novel therapies for neglected diseases like TB and Malaria.
-
-
-
Jubilant Pharmova Limited
-
India
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Senior Computational Chemist@Drug Discovery
-
Sep 2008 - Mar 2013
Supported several drug discovery projects (in-house/clients) involved in hit to lead identification and lead optimization by closely working with synthetic chemists and biologists. I have successfully applied Informatics and modeling techniques for the design of small molecule inhibitors for kinases, GPCRs, Ion Channels related to oncology, cardiovascular, metabolic and inflammatory diseases. Supported several drug discovery projects (in-house/clients) involved in hit to lead identification and lead optimization by closely working with synthetic chemists and biologists. I have successfully applied Informatics and modeling techniques for the design of small molecule inhibitors for kinases, GPCRs, Ion Channels related to oncology, cardiovascular, metabolic and inflammatory diseases.
-
-
-
VLife Sciences Technologies PVt. Ltd.
-
India
-
Software Development
-
1 - 100 Employee
-
Research Scientist@Informatics
-
Feb 2006 - Sep 2008
Conducted several programs for the identification of New Chemical Entities (NCE) and New Indication of existing Drugs (NID) by using computer aided drug design and chemoinformatics approaches. Design/development of new concepts/methodologies in V-Life Molecular Design Software suite and its validation. Involved in design of new molecules for various therapeutic targets entailed in metabolic disorders and oncology. Conducted several programs for the identification of New Chemical Entities (NCE) and New Indication of existing Drugs (NID) by using computer aided drug design and chemoinformatics approaches. Design/development of new concepts/methodologies in V-Life Molecular Design Software suite and its validation. Involved in design of new molecules for various therapeutic targets entailed in metabolic disorders and oncology.
-
-
Education
-
-
Devi Ahilya Vishwavidyalaya
Master of Pharmacy, Medicinal and Pharmaceutical Chemistry -
-
Jawaharlal Nehru Technological University, Anantapur
Ph.D (Pharmaceutical Sciences), Cheminformatics
Community
